

05-29-03

Gp #1646

#12/K.T.

PATENT

6/4

Suppl.  
I.D.S.



DOCKET NO.: ISIS-4853

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED  
JUN 02 2003  
TECH CENTER 1600/2900

In Re Application of:

Thazha P. Prakash, et al.

Confirmation No.: 5718

Application No.: 10/058,740

Group Art Unit: 1646

Filing Date: January 28, 2002

Examiner: Not Yet Assigned

For: METHODS OF MODULATING PHARMACOKINETICS OF  
OLIGONUCLEOTIDES

EXPRESS MAIL LABEL NO: EV2512844372US  
DATE OF DEPOSIT: May 28, 2003

EV2512844372US

Mail Stop DD  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

### SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

- ☒ In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in § 1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or

before the mailing date of a first Office Action after the filing of request for continued examination under § 1.114, no additional fee is required.

☐ In accordance with § 1.129(a), this Information Disclosure Statement is being filed in connection with ☐ the first or ☐ second After Final Submission, therefore:

☐ Certification in Accordance with § 1.97(e) is attached; or

☐ The fee of \$180.00 as set forth in § 1.17(p) is attached.

☐ In accordance with § 1.97(c), this Information Disclosure Statement is being filed after the period set forth in § 1.97(b) above but before the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311, or before an action that otherwise closes prosecution in the application, therefore:

☐ Certification in Accordance with § 1.97(e) is attached;  
or

☐ The fee of \$180.00 as set forth in § 1.17(p) is attached.

☐ In accordance with § 1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311 but before, or simultaneously with, the payment of the Issue Fee, therefore included are: Certification in Accordance with § 1.97(e); and the submission fee of \$180.00 as set forth in § 1.17(p).

☒ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.

- ☐ Copies of references listed on the attached Form PTO-1449 are enclosed herewith

## EXCEPT THAT:


- ☐ In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.
- ☐ In accordance with § 1.98(d), copies of the following references listed on the attached Form PTO-1449 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) for which a claim for priority under 35 U.S.C. § 120 have been made in the instant application:
- ☐ Copies of references [list as appropriate] listed on the attached Form PTO-1449 were previously cited by or submitted to the Patent and Trademark Office in prior Application No. , filed .
- ☐ If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

Enclosed is a copy of the PCT International Search Report dated May 2, 2003 (number 31 on the PTO-1449), which indicates the references considered to be relevant.

There are no listed references which are not in the English language.

Date: May 28, 2003

  
Emma R. Dailey  
Registration No. 48,491

WOODCOCK WASHBURN LLP  
One Liberty Place - 46th Floor  
Philadelphia, PA 19103  
Telephone: (215) 568-3100  
Facsimile: (215) 568-3439



#12

Sheet 1 of 2

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office	Docket No. ISIS-4853	Application No. 10/058,740
	Applicant Thazha P. Prakash, et al.	
	Filing Date January 28, 2002	Group 1646

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

31	Copy of the PCT International Search Report dated May 2, 2003 (PCT/US02/20940)
32	Prakash, T.P., et al., 2'-O-[2-(methylthio)ethyl]-modified oligonucleotide: an analogue of 2'-O-[2-(methoxy)-ethyl]-modified oligonucleotide with improved protein binding properties and high binding affinity to target RNA," <i>Biochemistry</i> , <b>2002</b> , 41, 11642-11648

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
-----------------	------------------------

**RECEIVED**  
JUN 02 2003  
TECH CENTER 1600/2900

**Form PTO-1449 Modified**

List of Patent and Publications  
Cited by Applicant  
(Use several sheets if necessary)

U.S. Department of Commerce  
Patent and Trademark Office

Docket No.  
ISIS-4853

Application No.  
10/058,740

Applicant  
Thazha P. Prakash, et al.

Filing Date  
January 28, 2002

Group  
1646

**RECEIVED**  
JUN 02 2003  
TECH CENTER 1600/2900

**U. S. PATENT DOCUMENTS**

Examiner Initial		Document No.	Date	Name	Class	Subclass
	33	6,147,200	11/14/00	Manoharan, et al.	536	23.1
	34	US 6,239,272 B1	05/29/01	Beigelman, et al.	536	24.5

**FOREIGN PATENT DOCUMENTS**

Examiner Initial		Document No.	Date	Country	Translation	
					YES	NO

**EXAMINER****DATE CONSIDERED**